Breastfeeding Pharmacy: Analgesics

Written by: Courtney Premer-Barragan, MD, PhD (NUEM ‘25)
Edited by: Adam Payne, MD (NUEM ‘24)
Expert Commentary by: Kelsea Caruso, PharmD

---

---

Expert Commentary

“Pump and dump” is definitely the easy way out for the emergency medicine provider, but this practice can have detrimental effects on the baby and on the mother. There is a false pretense that many medications are harmful to the breastfeeding infant, but this is not the case. The other consideration to have when thinking about medication use in breastfeeding is the medication effects on the mother’s lactation and the medication impact on breast milk production.

Ibuprofen by far has the most supporting evidence for use in breastfeeding women and this is a reasonable first line agent for treating many types of pain. Ketorolac is used frequently immediately after delivery and limited amount of drug is excreted in colostrum, but more may be excreted as milk supply increases thus increasing the risk of bleeding in the infant. Aspirin is excreted into breastmilk, and long-term use of high doses may cause bleeding along with metabolic abnormalities in the infant. That said, long-term use of low dose aspirin is likely safe.

If opioids are required for pain control, fentanyl is a reasonable choice for immediate pain control. Combination hydrocodone and acetaminophen is also an option when oral pain medications need to be utilized. The jury is (sort of) out on if oxycodone is safe during breastfeeding, and the baby should be monitored closely if oxycodone is selected for pain management.

Local anesthetics are very poorly absorbed by the infant, but still remain diligent about checking the specific maximum recommended dose for adults. My favorite database to find information on medications in lactation is LactMed, a database funded by the NIH. It is always safest to check this database before prescribing a medication to a lactating patient.

Kelsea Caruso, PharmD

Clinical Pharmacist

Department of Emergency Medicine

Northwestern Memorial Hospital

---

How To Cite This Post:

[Peer-Reviewed, Web Publication] Premer-Barragan, C. Payne, A. (2023, Jul 31). Breastfeeding Pharmacy Analgesics. [NUEM Blog. Expert Commentary by Caruso, K]. Retrieved from http://www.nuemblog.com/blog/breastfeeding-pharm-analgesics

---

Other Posts You May Enjoy

Droperidol

Written by: Adam Payne, MD (NUEM ‘24) Edited by: Julian Richardson, MD (NUEM ‘21) Expert Commentary by: Matt O' Connor, MD

---

---

Expert Commentary

Thanks to Dr. Payne & Dr. Richardson for putting this together!  I think this was well done, they’ve presented a concise overview of the safety and efficacy of droperidol. 

There’s a lot of utility in droperidol.  It’s great for nausea, migraines, and even as an adjunct for chronic pain.  It’s also a very good choice for agitation.  I use it most often for nausea.  It’s been shown to be as effective as odansetron, and more effective than metoclopramide.  Anecdotally, I find it works particularly well for gastroparesis and cannabinoid hyperemesis (with some low-concentration topical capsaicin cream), with less sedation than haloperidol.  For migraines, it has been shown to be as effective as prochlorperazine.  It works well for sedation in agitated patients as well; IV & IM it has a much faster onset than haloperidol, and so benzodiazepines typically do not have to be co-administered, reducing the level and duration of sedation and need for monitoring.     

The black box warning significantly limited droperidol’s availability, such that many of our newer graduates have not had any first-hand clinical experience with the medication.  If you’re not familiar with its use, don’t let the black box warning completely dissuade you.  Subsequent studies looking at emergency department droperidol use have shown it to be safe, and that complications related to QT prolongation are rare in typical doses.   As a rule of thumb, the dose of droperidol is about half of the dose of haloperidol for a given indication.  For nausea, migraine, or other pain, I usually start with 0.625-2.5mg IV, twice that IM, and can repeat dosing if needed (my most common starting dose is 1.25mg IV).  For agitation, usually 2.5-5mg IM, though up to 10mg IM has been shown likely to be safe.  Although it is prudent to be cautious, I think the literature supports droperidol’s use at appropriate doses in otherwise healthy patients.

Matt O’Connor, MD

Emergency Medicine Physician

BerbeeWalsh Department of Emergency Medicine

University of Wisconsin Hospitals and Clinics

---

How To Cite This Post:

[Peer-Reviewed, Web Publication] Payne, A. Richardson, J. (2021, Aug 30). Droperidol. [NUEM Blog. Expert Commentary by O’Connor, M]. Retrieved from http://www.nuemblog.com/blog/droperidol

---

Other Posts You May Enjoy

Ketamine Pain Control

Written by: Maren Leibowitz, MD (NUEM ‘23) Edited by: Matt McCauley, MD (NUEM ‘21) Expert Commentary by: Seth Trueger, MD, MPH

---

---

Expert Commentary

Thank you both for your excellent overview of ketamine analgesia. For me, the biggest thing is recognizing it is just not a big deal, and the biggest challenge is people's hesitancy to use it because it seems like a bigger deal than it is.

The main principles I highlight:

It's not hard, basically just give 0.1-0.3 mg/kg (20 mg is a good dose for most people).

The key is to give it in a small bag of saline, eg just mix it in 100ml and hang wide open (over about 20 min). This was demonstrated nicely in by Motov and colleagues (https://pubmed.ncbi.nlm.nih.gov/28283340/) and also resonates with my experience with patients.

This slow infusion minimizes (but does not eliminate) dysphoria/"feeling of unreality" some people get, and a slow hand push just does not do the trick. I also aim for 0.2mg/kg as rounding up can get people in the K-hole which is no fun (this is probably the only exception to my general rule of always use more, not less, anesthesia)

Ideally it's nice to do that dose as a bolus and then the same dose as a drip (eg 20mg over 20 min, followed by 20 mg per hour) but many EDs are unable to do that.

The easy way I think about it: a single does essentially replaces a dose of IV morphine- it does not require any more monitoring or have any increased risk of resp depression etc over morphine; ACEP, SEMPA & ENA have a statement on this. (https://www.acep.org/patient-care/policy-statements/sub-dissociative-dose-ketamine-for-analgesia/) It's just simply not sedation or dissociation (hence the term "sub-dissociative") and I have gotten in the habit of calling it "ketamine analgesia."

Perhaps the biggest downside is that for really severe pain, it works well but sometimes only as it's actively dripping in.

The situations I think about using ketamine analgesia are severe pain with contraindications to opioids (eg a patient with a fracture with a history of OUD who does not want opioids) or patients with severe pain where high doses of opioids are not sufficiently helping (eg malignant fractures, severe burns).

Theoretically we could use SDK all the time but there's a chicken/egg problem: we don't use it much, so people aren't very comfortable (plus some other various institutional/historical discomfort with ketamine in some sectors); also, realistically it doesn't last as long as IV opioids. Ideally I would probably use bolus + drip frequently if there weren't barriers.

Dr. Seth Trueger, MD

Assistant Professor of Emergency Medicine
Northwestern Memorial Hospital

---

How To Cite This Post:

[Peer-Reviewed, Web Publication] Leibowitz, M. McMauley, D. (2021, March 29.) Ketamine Pain Control. [NUEM Blog. Expert Commentary by Trueger, S]. Retrieved from http://www.nuemblog.com/blog/ketamine-pain-control.

---

Other Posts You May Enjoy

Journal Club: Do Emergency Physician Opioid Prescribing Practices Impact Long-Term Opioid Use?

Written by: Jon Andereck, MD (NUEM PGY-3) Edited by: Rachel Haney, MD, (NUEM Graduate 2017) Expert
commentary by:  Seth Trueger, MD

---

Introduction

View fullsize

Figure 1. Opioid Pain Reliever Sales, Related Treatment Admissions, and Related Deaths from 1999-2010 (CDC).

Over the past two decades, rates of opioid prescribing in the United States have skyrocketed, with the total amount of opioids distributed quadrupling from  1999 to 2010 (see Fig. 1). [1]  Rates of opioid related unintentional overdoses and deaths have risen in concurrent fashion, from 4,030 in 1999 to 14,800 in 2008. Public health experts, policy makers, and physicians have slowly come around to acknowledging the epidemic of opioid abuse now facing the country.

Much like in other care settings, there has been an increasing push to reduce the volume of opioids prescribed from the ED. The exact role of Emergency Department (ED) opioid prescriptions in this epidemic has been difficult to quantify. Among people aged 10-29, EDs represented 12% of opioid prescriptions and ranked as the third most common setting for which opioids were prescribed. [2]

Indeed, nearly 4 in 5 heroin users reported prior exposure to non-medical prescription pain relievers, and prior exposure to narcotic pain medications carried a 19-fold increased risk of future heroin use. [3] A study from 2014 estimated that as many as 13.8% of patients discharged from ED's across the country in 2010 were written a prescription for opioid pain medications, up from 11% in 2005. [2] Still, a large amount of uncertainty persists about the true impact of prescribing habits of Emergency Physicians (EP's) on the incidence of narcotic abuse. This study helps shed some light on how EP prescribing practices impact long-term narcotic use.

---

Study

Barnett ML, Olenski AR, Jena AB. Opioid-Prescribing Patterns of Emergency Physicians and Risk of Long-Term Use. N Engl J Med. Feb 16 2017. 376(7): 663-673.

Study Design

Retrospective analysis.

Population

Medicare Beneficiaries who visited any ED in the US from Jan 1, 2008 – Dec 31, 2011 who had not received an opioid prescription in the preceding 6 months and who were not admitted to the hospital on the index ED visit studied. Patients with cancer or on hospice were also excluded.

Measurement Protocol

Using Medicare Part D data, the authors calculated the morphine equivalents dispensed both in the 7 days following the index ED visit and any further opioid prescriptions over the following 12 months.

Treating EPs were categorized as either high-intensity or low-intensity opioid prescribers based on comparison with their peers at the same hospital. The authors calculated the percentage of patients that filled an opioid prescription after seeing any provider in a given hospital, and then divided providers into quartiles of rates of opioid prescribing within their own hospital. Physicians in the top quartile were designated high-intensity prescribers; those in the bottom quartile were designated low-intensity prescribers.

Outcome Measures

The primary outcome of interest was rate of long-term opioid use among patients in the 12 months following a visit in which they were seen by either a low-intensity or high-intensity opioid prescriber. Long-term use was defined as at least 180 days of opioids supplied in the 12 months after the initial ED visit, excluding the first 30 days following the ED visit.

Secondary measures included rate of hospital encounters possibly related to the adverse effects of opioids in the 12 months following the index ED visit. The authors also measured repeat ED visits at 14 and 30 days for the same primary diagnosis to assess for possible undertreated pain.

Results

Long-term opioid use was significantly higher among those treated by high-intensity prescribers, with an odds ratio of 1.3 (p<0.001) and an absolute rate of 1.51% as compared to 1.16% in the low-intensity group. The authors calculate a number needed to harm of 48 patients receiving an opioid prescription to lead to one excess long-term opioid user.

Long-term opioid use increased in a stepwise fashion for patients treated by physicians in each quartile of prescribing intensity (Fig 1).

A total of 377,629 patients were included in this retrospective analysis; 215,678 were seen by low-intensity EPs and 161,951 were seen by high-intensity EPs. Characteristics of each patient population were similar, though several of these were significant given the large sample size (see Table 1).

Over three times as many patients seen by a high-intensity prescriber were discharged with an opioid prescription than those seen by a low-intensity prescriber (24.1% vs. 7.3%), though there was no difference between the two groups in the median dose of morphine equivalents per prescription.

View fullsize

Figure 1

View fullsize

Table 1

In the secondary analysis, the authors found a small but significant increase in rates of opioid-related encounters (OR 1.03, p = 0.02) as well as ED visits for fall or fracture (OR 1.07, p < 0.001) for patients treated by high-intensity prescribers. In contrast, there was no difference in rates of hospital encounters for non-opioid related complaints. Additionally, rates of short-term ED visits for the same chief complaint were no different at 14 or 30 days for patients treated by either low- or high-intensity prescribers (See Table 3).

View fullsize

Table 3

Interpretation

This study does an impressive job of looking at an important but poorly understood issue in the field of emergency medicine – how do prescribing practices of physicians affect long-term opioid abuse their patients?

This retrospective study design is limited in that it was not randomized-controlled, but it was the most logical design to answer the question at hand. The number of patients included was certainly adequate to detect a meaningful difference. The study was limited by the fact that only Medicare beneficiaries were studied, in part because this was the most accessible database for such a large retrospective study. However, it therefore excludes many in the 19-39 age range in which long-term abuse potential is highest. Designing a randomized-controlled trial to attempt to answer this question would be difficult as it would require standardization of discharge prescriptions; few physicians would be amenable to ceding their right to determine the analgesic plan for their own patients.

The primary outcome of interest – long-term opioid use among patients seen by either type of provider – demonstrated that there is a correlation between high-intensity prescribers and long-term opioid use among patients they see. The authors calculate a number needed to harm (NNH) of 48 among patients prescribed opioids on discharge. This means that for every 48 patients given a discharge prescription for an opioid analgesic by a high-intensity prescriber, one will go on to use opioids long-term (as defined by this study) that could have been avoided if the patient had been seen by a low-intensity prescriber.

View fullsize

One of the most interesting results from this study is not even the question the authors set out to answer, but is the difference in opioid prescribing rates between high-intensity and low-intensity prescribers. This difference was over three-fold (7.3% to 24.1%) and represents an extraordinarily wide practice variability that underscores the lack of standard practice for opioid use. However, this variation was only in the number of prescriptions written and not for the amount of morphine equivalents per prescription as demonstrated in Fig. S3 above.

The counter-measure of pain control adequacy is an important one. The authors attempt to address whether patients treated by low-intensity providers had inadequate analgesia at home. While this question was not directly answered by the study, a surrogate measure of return visits to the ED with the same chief complaint demonstrated no significant difference between the two groups, which suggests but does not prove that there was no meaningful difference in analgesia between the groups.

Is this article practice changing? Perhaps. It does provide evidence that there is a correlation, small though it may be, between prescribing practices of EPs and long-term opioid use of patients. There are also small but significant differences in complications from the opioids given by high-intensity prescribers. The study further highlights the profound variability among EPs regarding their opioid prescribing practice, which I argue is an area to target for improvement especially without any known deficiency of pain treatment by doing so. We can all strive to only prescribe opioids that are truly necessary to treat acute pain, and this article serves as further motivation that over-prescribing can in fact cause our patients direct harm.

---

Take Home Points

•  Variability of opioid prescribing within departments is large
•  Opioid prescribing patterns do have an impact on long-term opioid use
•  Fewer opioids do not lead to worse pain control, at least as measured by the return rate to the ED

---

Expert Commentary

This is a great overview of an impactful article. While ultimately there will always be some variation in opioid prescribing (by chance, some physicians will likely see more patients with more painful conditions), this paper suggests that the prescriber variability is high and its not due to chance. Regardless, my takeaway here is that there does seem to be a dose-response to opioid prescribing in the ED and longer term opioid use.

Both the sheer scale and physicians’ role in the opioid epidemic is startling and a number of factors are at play. Years of focus on oligo-analgesia were likely a mix of genuine concern for undertreating pain but unfortunately also driven by those with specific financial interests. Similarly, the increasing focus on patient satisfaction/experience and even with the link to payments, I suspect physicians are too quick to shift blame to others and we need to prescribe more responsibly. While most emergency department opioid prescriptions are short (75% are for 20 pills or fewer [4]), as Barnett and others have shown, a startling fraction of ED patients receive opioid prescriptions. And to borrow from Lewis Nelson, everyone who is addicted to opioids had to have had a first exposure.

Of course there are no easy answers – plenty of patients we see in the emergency department are in substantial pain, and we do not have a lot of tools. But it is not hopeless. My approach to pain management is similar to patients with URIs and antibiotics: sometimes we cut corners (“they’re just here for a z pack / Norco prescription”) and underestimate how satisfied our patients can be being taken care of by a physician who cares and explains things. Some of the things I focus on:

1.  Acknowledge the patient’s pain: just because I’m not writing for a ton of opioids doesn’t mean I don’t believe they’re not in pain
2.  Set realistic goals: I don’t have a silver bullet to make pain go away. My goal is to make their pain manageable, not gone.
3.  Emphasize our priorities: Our main goal in the ED is to make sure there isn’t anything dangerous causing the patient’s symptoms.
4.  The door isn’t shut when I discharge the patient: “The good news is you don’t need an MRI now but you do need to follow up with your primary doctor over time who will keep an eye on your symptoms and help determine if you do eventually need more testing or to see a specialist.”
5. Information, information, information: what concerning symptoms to look for at home, when to call your doctor, when to come back to the ED.
6.  What to do for symptoms: What works well for this? I find a lot of patients are very happy to hear me thoughtfully say “what works really well for this is prescription-strength ibuprofen.” I’ve also had a lot of success with lidocaine patches. Anecdotally they seem to work well, but more importantly, I think it demonstrates to the patient that we’re paying attention and being thoughtful (especially as I need to explain that sometimes insurance doesn’t cover them well but there are over the counter versions so here is how to approach that…)

Incidentally I rarely prescribe or co-prescribe benzodiazepines as we have some data they aren’t very helpful (e.g. Friedman [5]) and that we vastly underestimate their harms, particularly when patients take both opioids and benzos (e.g. Sun [6]).

We have a tight needle to thread between oligoanalgesia and the opioid epidemic, but right now I think it’s clear that the pendulum has swung too far. I don’t think we can nor should stop using opioids altogether (yet) but we can be thoughtful and careful as we care for our patients.

Seth Trueger MD MPH

Assistant Professor of Emergency Medicine, NUEM

---

Posts You May Also Enjoy

---

How to cite this post

[Peer-Reviewed, Web Publication]  Andereck J,  Haney R  (2018, Jan 29). Journal Club:  Do Emergency Physician Opioid Prescribing Practices Impact Long-Term Opioid Use? [NUEM Blog. Expert Commentary By Trueger S]. Retrieved from http://www.nuemblog.com/blog/opioids. 

---

Resources

1.  “Vital Signs: Overdoses of Prescription Opioid Pain Relievers --- United States, 1999-2008.” Morbidity and Mortality Weekly Report. Centers for Disease Control and Prevention. Nov 4, 2011. 60(43): 1487-1492. < https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6043a4.htm#fig2>. 
2.  Cantrill SV, Brown MD et al. Clinical Policy: Critical Issues in the Prescribing of Opioids for Adult Patients in the Emergency Department. From the American College of Emergency Physicians Opioid Guideline Writing Panel. Ann Emerg Med. 2012. 60:499-525.
3.  Muhuri PK, Gfroerer JC, and Davies MC. Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States. Center For Behavioral Health Statistics and Quality. CBHSQ Data Review. August 2013.
4. Hoppe JA, Nelson LS, Perrone J, Weiner SG. Opioid Prescribing in a Cross Section of US Emergency Departments. Ann Emerg Med. 2015 Sep;66(3):253-259.
5. Friedman BW, Irizarry E, Solorzano C, Khankel N, Zapata J, Zias E, Gallagher EJ. Diazepam Is No Better Than Placebo When Added to Naproxen for Acute Low Back Pain. Ann Emerg Med. 2017 Aug;70(2):169-176.
6. Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017 Mar 14;356:j760. doi: 10.1136/bmj.j760.